Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: construction  management  building  construction  manager  civil  engineering  general  contractor  jamil  soucar  westwind  cosprod  new  volvo  xc40  suv  xc90  car  auto  storage  commercial  multivu  8163951  fda  brain  cancer  health  healthcare  treatment  medicine  glioma  multivu  7944251  health  medicine  pharmaceuticals  gw  manufacturing  drugs  epileptic  treatment  pills  multivu  8109951  csl  behring  global  biotherapeutics  medicine  study  research  fda  healthcare  health  multivu  8056151  brookdale  senior  elderly  parents  hospice  research  hospital  wellness  health  multivu  7722159  plane  aurora  flight  sciences  aircraft  technology  lightningstrike  vtol  xplane  darpa  vertical  multivu  7617851  johnson  johnson  biopharmaceutical  idea  pharma  neuroscience  medicine  health  innovation  multivu  7770851  immobilier  de  la  technologie  des  services  convaincre  la  france  mode  de  vie  de  lentreprise  de  gestion  en  ligne  multivu  immobilier  de  la  technologie  des  services  convaincre  la  france  mode  de  vie  de  lentreprise  de  gestion  en  ligne  multivu  7  research  astro  science  cancer  early  stage  breast  cancer  health  technology  advancement  doctors  multivu  7661231  research  astro  science  cancer  early  stage  breast  cancer  health  technology  advancement  doctors  multivu  7661231 
Search // phase
Results 1-12 of 61 for ' phase ' (0 seconds)
Volvo Cars today declares an end to a problem faced daily by drivers around the globe: a lack of suitable and functional storage space inside their car. With its innovative approach inside the new XC40 small city SUV, set to be launched in the coming weeks, Volvo Cars takes the lead in the small premium SUV segment in terms of space, storage and all-round functionality. The highly anticipated XC40 from Volvo Cars will complete the company’s SUV line-up that also features the top-of-the-range large XC90 and the mid-sized XC60. As part of the XC40’s development phase, Volvo Cars’ customer research team spent considerable time investigating how city dwellers around the globe use their car on a daily basis – and, more importantly, how they store their belongings in their cars. Customers were also asked how they would like to see the interiors of their cars improved. To view the multimedia release go to: https://www.multivu.com/players/uk/8163951-end-clutter-volvo-cars-XC40-small-SUV/
Tags // new  volvo  xc40  suv  xc90  car  auto  storage  commercial  multivu  8163951 
Categories // Miscellaneous 
Added: 1862 days ago by MultiVuVideos
Runtime: 2m27s | Views: 370 | Comments: 1
Not yet rated
 

 

 

A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma. The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor. To view the multimedia release go to: https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Categories // Miscellaneous 
Added: 1925 days ago by MultiVuVideos
Runtime: 4m28s | Views: 381 | Comments: 1
Not yet rated
 

 

 

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Categories // Miscellaneous 
Added: 1952 days ago by MultiVuVideos
Runtime: 3m35s | Views: 363 | Comments: 0
Not yet rated
 

 

 

Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE. To view the multimedia release go to: https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Categories // Miscellaneous 
Added: 2016 days ago by MultiVuVideos
Runtime: 2m41s | Views: 372 | Comments: 0
Not yet rated
 

 

 

After analyzing millions of Internet visits and interviewing scores of consumers, Brookdale Senior Living has built a new website based on fresh insights into what’s most important to families searching for senior care. The first phase, which is a $4 million investment, went live on brookdale.com mid-August. “With Brookdale’s website attracting more than 500,000 visits every month, it’s imperative to make it as useful to consumers as possible,” said David Cygan, Brookdale’s senior vice president of marketing. “As the nation’s largest senior living provider, we know our website is a primary source of information, with many people coming to us first as they embark on this journey,” Cygan said. “It’s important that we offer substantive resources that make it easier to find help in evaluating senior care options.” More than 80 percent of adult children turn to the Internet when they look for care for an aging parent, according to the company’s research. To view the multimedia release go to: http://www.multivu.com/players/English/7722159-new-brookdale-senior-living-website/
Categories // Miscellaneous 
Added: 2214 days ago by MultiVuVideos
Runtime: 0m50s | Views: 524 | Comments: 0
Not yet rated
 

 

 

Aurora Flight Sciences announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company the prime contract for Phase 2 of the Agency’s Vertical Takeoff and Landing Experimental Plane (VTOL X-Plane) program. VTOL X-Plane seeks to develop a technology demonstrator that could: • Achieve a top sustained flight speed of 300 kt-400 kt • Raise aircraft hover efficiency from 60 percent to at least 75 percent • Present a more favorable cruise lift-to-drag ratio of at least 10, up from 5-6 • Carry a useful load of at least 40 percent of the vehicle’s projected gross weight of 10,000-12,000 pounds The Aurora team’s design for its unmanned aircraft, named LightningStrike, seeks to provide an approximately 50-percent increase in speed over existing VTOL aircraft designed for comparable mission applications. To view the multimedia release go to: http://www.multivu.com/players/English/7617851-aurora-flight-sciences-vtol-xplane-darpa/
Categories // Miscellaneous 
Added: 2400 days ago by MultiVuVideos
Runtime: 1m49s | Views: 584 | Comments: 0
Not yet rated
 

 

 

The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running. The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it? The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia). To view the multimedia release go to: http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Categories // Miscellaneous 
Added: 2408 days ago by MultiVuVideos
Runtime: 3m36s | Views: 491 | Comments: 0
Not yet rated
 

 

 

Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif ! Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien. To view the multimedia release go to: http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
Categories // Miscellaneous 
Added: 2432 days ago by MultiVuVideos
Runtime: 2m32s | Views: 495 | Comments: 0
Not yet rated
 

 

 

Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif ! Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien. To view the multimedia release go to: http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
Tags // immobilier  de  la  technologie  des  services  convaincre  la  france  mode  de  vie  de  lentreprise  de  gestion  en  ligne  multivu  7 
Categories // Miscellaneous 
Added: 2432 days ago by MultiVuVideos
Runtime: 0m30s | Views: 469 | Comments: 0
Not yet rated
 

 

 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated. Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal. “We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.” To view the multimedia release go to: http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Categories // Miscellaneous 
Added: 2529 days ago by MultiVuVideos
Runtime: 1m25s | Views: 581 | Comments: 0
Not yet rated
 

 

 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated. Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal. “We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.” To view the multimedia release go to: http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Categories // Miscellaneous 
Added: 2529 days ago by MultiVuVideos
Runtime: 3m4s | Views: 562 | Comments: 0
Not yet rated
 

 

 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated. Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal. “We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.” To view the multimedia release go to: http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Categories // Miscellaneous 
Added: 2529 days ago by MultiVuVideos
Runtime: 2m3s | Views: 675 | Comments: 0
Not yet rated
 

 

 

Page 1 of 6  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2022 ClipMoon.com. All rights reserved.